Bliss GVS Pharma Share Price

NSE
BLISSGVS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Bliss GVS Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
22.2
TTM PE Ratio
Below industry Median
26.4
Price to Book Ratio
Low in industry
1.7
Dividend yield 1yr %
Below industry Median
0.3
TTM PEG Ratio
PEG TTM is negative
-0.9

Bliss GVS Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Bliss GVS Pharma Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
217.68 Cr
183.64 Cr
198.13 Cr
200.72 Cr
211.88 Cr

Bliss GVS Pharma Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
798.98 Cr
769.37 Cr
778.95 Cr
597.43 Cr
728.49 Cr

Bliss GVS Pharma Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
25.69 Cr
22.11 Cr
-4.91 Cr
29.07 Cr
43.04 Cr

Bliss GVS Pharma Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
81.58 Cr
76.73 Cr
23.13 Cr
73.97 Cr
95.25 Cr

Bliss GVS Pharma Ltd shareholding Pattern

Promoter
34.8%
Foreign Institutions
12.1%
Domestic Institutions
6.6%
Public
46.5%
Promoter
34.9%
Foreign Institutions
13.2%
Domestic Institutions
6.6%
Public
45.3%
Promoter
35%
Foreign Institutions
14.7%
Domestic Institutions
6.6%
Public
43.7%
Promoter
35%
Foreign Institutions
15.4%
Domestic Institutions
6.6%
Public
43.1%
Promoter
35.1%
Foreign Institutions
16.3%
Domestic Institutions
6.6%
Public
42%
Promoter
35.1%
Foreign Institutions
16.5%
Domestic Institutions
6.6%
Public
41.7%

Bliss GVS Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
10
Bearish Moving Averages
6
5Day EMA
166.30
10Day EMA
165.00
12Day EMA
163.80
20Day EMA
158.40
26Day EMA
154.70
50Day EMA
145.00
100Day EMA
135.20
200Day EMA
125.90
5Day SMA
168.40
10Day SMA
165.50
20Day SMA
159.80
30Day SMA
147.50
50Day SMA
138.90
100Day SMA
132.00
150Day SMA
123.90
200Day SMA
121.60
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
248415 Rs
865682 Rs
Week Rs
312879 Rs
1003316 Rs
Month Rs
644373 Rs
2623344 Rs
Resistance & Support
165.15
Pivot
Resistance
First Resistance
170.19
Second Resistance
179.24
Third Resistance
184.28
Support
First Support
156.10
Second support
151.06
Third Support
142.01
Relative Strength Index
55.90
Money Flow Index
61.07
MACD
9.04
MACD Signal
9.56
Average True Range
9.22
Average Directional Index
33.27
Rate of Change (21)
24.86
Rate of Change (125)
55.15

Bliss GVS Pharma Ltd Company background

Founded in: 1984
Managing director: Gagan Harsh Sharmma
Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals Pharmaceuticals India Private Limited in 1984. The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company, founded in 1984 with the objective of ensuring healthcare access worldwide, is one of the pharmaceutical industries fastestgrowing businesses. The Company has a robust portfolio of more than 250 products and is a global leader in the dosage forms for suppositories and pessaries. It has a strong foothold in Sub Saharan Africa. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Palghar which is WHO GMP approved. The business operates five cuttingedge production facilities that adhere to WHOGMP, EUMP, ISO 14001 and OHSAS 45001 standards.The company has a dedicated the RD Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific Industrial Research (DSIR), Government of India.The company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharmas RD center, received approval from Government of Indias Department for Scientific Industrial Research (DSIR).During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana.During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent.During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria. Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017,The companys investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth.The Company set up a multidosage facility at Vevoor, Maharashtra in 2019. The first phase commissioned earlier in March, 2020, primarily for Tablets, Capsules, Dry Syrups, and Sachets. While the second phase commenced construction in January, 2021.
Read More

Bliss GVS Pharma Ltd FAQs

Bliss GVS Pharma Ltd shares are currently priced at 158.78 on NSE and 159.5 on BSE as of 12/20/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Bliss GVS Pharma Ltd [BLISSGVS] share was 29.24. The Bliss GVS Pharma Ltd [BLISSGVS] share hit a 1-year low of Rs. 92.15 and a 1-year high of Rs. 179.8.

The market cap of Bliss GVS Pharma Ltd is Rs. 1697.98 Cr. as of 12/20/2024 12:00:00 AM.

The PE ratios of Bliss GVS Pharma Ltd is 21.04 as of 12/20/2024 12:00:00 AM.

The PB ratios of Bliss GVS Pharma Ltd is 1.65 as of 12/20/2024 12:00:00 AM

You can easily buy Bliss GVS Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -